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Editorial on the Research Topic:
Cancer Vaccines: Time to Think Differently!
Although the advent of checkpoint inhibitors has revolutionised immunotherapy, the surge of
optimism has been quickly dampened by the fact that only some cancers and only a proportion of
cancer patients truly benefit from these treatments when they are administered as a monotherapy.
The era of combined therapy is now upon us and many clinical trials are now combining drugs,
vaccines and checkpoint inhibitors with the aim to amplify the ability of the immune system to
recognize and eradicate cancer. This Frontiers Research Topic entitled “Cancer vaccines: Time to
think differently!” has collated 16 contributions from experts who are exploring a range of novel
treatment approaches that are centred on vaccine-based approaches for triggering protective anti-
cancer immunity in pre-clinical animal models and patients.
In a mouse model of head and neck squamous cell carcinoma, Jin et al. show that combining
radiation and cetuximab (an epidermal growth factor receptor inhibitor) increased intra-tumoral
infiltration of NK cells and CD8+ T cell and enhanced the expression of PD-L1 (checkpoint pathway
ligand) by tumour cells. As a consequence, this heightened the susceptibility of the tumour to PD-L1
antibody treatment and thereby increased durable tumour regression and the survival of mice when all
three treatments were combined. However, this is only one example of many new and different strategies
that are currently being investigated, as has been highlighted in the review article by Chen et al. Although
the current focus is very much on ‘checkpoint blockade’, there is no doubt that future combination
strategies are likely to include metabolic and epigenetic therapies to circumvent immune escape
mechanisms and block intricate immunosuppressive mechanisms in the tumour microenvironment
(TME), as discussed by Chen et al. or the use of in situ ablation, as discussed by van den Bijgaart et al.
The successful application of platforms employing mRNA-based cancer vaccine technology to
SARS-CoV-2 vaccines and the remarkable success of these mRNA-based formulations against
COVID-19 has once again highlighted the potency of this novel approach in cancer. This success
has reawakened awareness of the potential potency of earlier approaches to vaccines such as the use
of dendritic cells (DCs), as shown by Kumbhari et al. who has used a theoretical approach which
applies a mathematical model and simulations to demonstrate how vaccine-induced avidity selectionorg October 2021 | Volume 12 | Article 7713191
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immature DCs has the potential to promote the selective expansion
of high-avidity cytotoxic T lymphocytes (CTLs) and lead to tumour
regression. “Classical” approaches to the generation of DCs for use in
immunotherapy may also still leave room for improvement, as
discussed by Calmeiro et al. Alternatively, using delivery systems
such as the DNA-based ImmunoBody® which directly targets
immature DCs in vivo offers the opportunity to simultaneously
trigger immunity to two antigens, HAGE and WT1, as described by
Almshayakhchi et al. Although predicted epitopes derived from
vaccines can be used to monitor CD8+ T cell responses ex vivo in
clinical trial settings as a means to gauge the success of T cell
vaccines, Lehmann et al. showed that there was no correlation
between the ranking of epitopes on the prediction scale and their
actual immune dominance. One would therefore need to screen
large vaccine-derived peptide pools to increase the accuracy of the
targeted response.
Data from murine models presented by Bikorimana et al.
demonstrate that thymoproteasome-based proteasomal alterations
can trigger potent T cell immunity when used as part of an
engineered mesenchymal stromal cell-based vaccine. Although
vaccination led to the recruitment of macrophages and DCs, the
immunotherapeutic effect was mediated by cross-priming-dependent
DCs. It was also noted that an interaction between vaccine and
monocytes/macrophages impaired T cell activation, as a consequence
of which the depletion of monocytes/macrophages prior to
vaccination increased efficacy. In an additional article on the use of
DC-based vaccines, Stevens et al. review nearly 20 years of DC-based
immunotherapy in lung cancer. They conclude that combining DC-
based immunotherapy with other cancer therapies, such as
chemotherapy, radiotherapy and/or checkpoint inhibition may
potentially improve vaccine efficacy. Clinical studies testing these
hypotheses are underway.
Alternative new and previously considered cancer vaccine
delivery approaches are also being (re)-evaluated and discussed in
the field. Oladejo et al. consider Listeria monocytogenes as a vaccine
vector. They discuss recent clinical experience with Listeria-based
immunotherapies and recent advances in the development of
improved Listeria-based vaccine platforms and their utilization. In
an elegant approach by Otterhaug et al., a subunit cancer vaccine is
combined with a photochemical compound in a so-called
photochemical internalisation (PCI). The intradermal
administration of the vaccine is followed by its uptake into skin
antigen presenting cells (APCs). Subsequent light treatment disrupts
vaccine-containing endosomes and triggers the release of antigen to
the cytosol for presentation to major histocompatibility (MHC) class
I molecules and stimulation of CD8+ T cell responses. This first-in-
human phase I study in healthy volunteers assessed safety,
tolerability, and immune responses to PCI vaccination in
combination with the adjuvant poly-ICLC. Another approach to
cancer vaccination is presented by Zhang et al. who describe a
personalized vaccination regime that could be applied for both the
therapeutic and prophylactic treatment of lung cancer. This is based
on the derivation of lung cancer cells from induced pluripotent stem
cells (iPSCs), which are modified to express Cre-dependent tumour
antigens. Subsequent viral delivery (e.g. via Adenovirus) of Cre
activated exogenous driver mutations and resulted in theFrontiers in Immunology | www.frontiersin.org 2transformation of lung cancer cells. This “Virus-Infected
Reprogrammed Somatic cell-derived Tumour cell vaccination”
(VIReST), primed tumour-specific T cell responses that
significantly prolonged survival in mouse models of lung cancer.
Finally, a vaccine cannot be better than its adjuvant. Especially
in the context of cancer vaccines, the strength and quality of
adjuvants is essential if one is to overcome the self-tolerance
barrier of barely immunogenic tumour antigens. As discussed by
Cuzzubo et al., the use of carefully selected adjuvants to improve
vaccine potency in older patients becomes crucial and although
some cancers can be completely protected against by vaccinating
early in life, as discussed by Crews et al., the majority will rely on
the use of adjuvants capable of inducing efficient and long lasting
TRM cells. These may have a progenitor exhausted phenotype such
as the one described by León-Letelier et al., which have been
shown to control the disease and lead to better responses to PD-1
immunotherapy. Adjuvants may also offer a means to overcome
the immune suppressive TME, as discussed by Paston et al.
Cancer develops over many years during which time cells have
accumulated numerous genetic alterations and been continuously
“sculpted”/modified by the immune system. This leads to the
emergence of one fully malignant escapee which then goes on to
form a tumour having an immunosuppressive TME. However,
although one fully malignant cell represents the origin of tumour
growth and spread, many other cells at different stages of potential
disease progression remain even if the tumour has been cured.
Hence, in addition to the challenging task of eliminating the primary
tumour to prevent metastasis and relapse, future treatments will
have to take this into consideration. There is no longer any doubt
that our lifestyle and age will affect our immune system and the
entirety of the soma, all of which will influence our ability to
respond to novel combinatorial treatments such as those detailed in
this Research Topic. It is our firm belief that we will not be able to
cure/eradicate cancer unless we are able to harness ways to
implement a more holistic approach to cancer treatments (and
cancer prevention in the first place).AUTHOR CONTRIBUTIONS
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